PMID- 37750637
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20231019
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 17
DP  - 2023 Sep
TI  - Effect of empagliflozin use on monocyte high-density lipoprotein ratio and plasma 
      atherogenic index in obese and non-obese type 2 diabetic patients.
PG  - 8090-8100
LID - 33569 [pii]
LID - 10.26355/eurrev_202309_33569 [doi]
AB  - OBJECTIVE: Diabetes mellitus (DM) is a metabolic disorder marked by 
      hyperglycemia, caused by impaired insulin secretion and activity. Chronic 
      inflammation holds a significant role in the development, progression, and 
      complications of DM and obesity. There are publications reporting that the 
      monocyte/ high-density lipoprotein (HDL)-C ratio (MHR) and plasma atherogenic 
      index (PAI) could be used as indicators of systemic inflammation. In the present 
      study, we aimed to explore the effect of empagliflozin, an inhibitor of 
      sodium-glucose co-transporter 2 (SGLT2), on MHR and PAI in obese and non-obese 
      type 2 diabetes mellitus (T2DM) patients. PATIENTS AND METHODS: A total of 125 
      patients who presented to the outpatient clinics of Tokat Gaziosmanpasa 
      University Hospital between January 2019 and January 2023 with a diagnosis of 
      T2DM and were started on 25 mg empagliflozin and used for a minimum of 24 weeks 
      were included in the study. The patients' age varied between 18-75 years, were 
      without chronic liver disease, chronic renal failure, infection, or inflammatory 
      disease, and were not on drugs affecting bone marrow. The patients were 
      categorized into two groups, obese and non-obese, according to their body mass 
      index (BMI). The data obtained were statistically analyzed using the IBM SPSS 
      Statistics 25 software package. RESULTS: The mean age of the patients was 57.5 +/- 
      10.9 years. Of the patients, 59.2% (n = 74) were female, and 40.8% (n = 51) were 
      male. The mean HbA1c percentage was 8.99 +/- 2.18% prior to empagliflozin treatment 
      and significantly decreased to 7.68 +/- 1.80% after empagliflozin use (p < 0.05). 
      The mean monocyte HDL-C ratio (MHR) pre- and post-empagliflozin treatment was 
      16.22 +/- 6.31 and 13.77 +/- 5.29, respectively, and these values significantly 
      differed from each other (p < 0.05). The mean plasma atherogenic index (PAI) of 
      the patients before empagliflozin treatment was 0.62 +/- 0.28, whereas, after the 
      treatment, it significantly reduced to 0.52 +/- 0.27 (p < 0.05). While MHR and PAI 
      statistically significantly decreased with the use of empagliflozin, there was no 
      difference between the obese and non-obese patient groups in terms of MHR and PAI 
      results. CONCLUSIONS: Studies in the literature show that the decrease in MHR and 
      PAI leads to a decline in inflammation. MHR and PAI are inexpensive and practical 
      markers to assess cardiovascular disease risk and inflammation in diabetic 
      patients. This finding indicates that MHR and PAI can be used as inflammation 
      markers in patients on empagliflozin treatment.
FAU - Sivgin, H
AU  - Sivgin H
AD  - Department of Internal Medicine, Faculty of Medicine, Tokat Gaziosmanpasa 
      University, Tokat, Turkey. hakan.sivgin@gop.edu.tr.
FAU - Cetin, S
AU  - Cetin S
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - HDC1R2M35U (empagliflozin)
RN  - 0 (Lipoproteins, HDL)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - Middle Aged
MH  - Aged
MH  - Adolescent
MH  - Young Adult
MH  - Adult
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Monocytes
MH  - Inflammation/drug therapy
MH  - Lipoproteins, HDL
MH  - Obesity/complications/drug therapy
EDAT- 2023/09/26 13:42
MHDA- 2023/09/27 06:42
CRDT- 2023/09/26 08:33
PHST- 2023/09/27 06:42 [medline]
PHST- 2023/09/26 13:42 [pubmed]
PHST- 2023/09/26 08:33 [entrez]
AID - 33569 [pii]
AID - 10.26355/eurrev_202309_33569 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8090-8100. doi: 
      10.26355/eurrev_202309_33569.